Scientists discover drug to stop SARS-COV2 replication

0
118

RESEARCHERS say that the Ebselen compound can inhibit the replication of SARS-CoV-2 in the laboratory, and could combat COVID-19.

  A group of researchers has identified a compound called Ebselen (2-phenyl-1,2-benzoselenazol-3(2H) one) that they say could be used to potentially stop the replication of SARS-CoV-2, the virus causing the COVID-19 pandemic. The study was conducted at the Politecnico di Milano, Italy.

  With regular news updates and space for you to discuss and publish your Coronavirus research, our COVID-19 research hub has everything you need to keep up to date with R and D during the pandemic.

  According to the researchers, two important aspects of the propagation of a virus are its ability to enter the host’s cells and then to replicate in infected cells. For SARS-CoV-2, the Mpro protein plays an important role in the replication and transcription of the coronavirus. Mpro therefore represents a particularly promising target for blocking the virus itself because a compound that inhibits Mpro blocks the virus, the researchers say.

  Testing and screening approximately 10,000 compounds, the researchers found that Ebselen proved to be the most potent inhibitor of Mpro in the laboratory. 

  “We have identified that the selenium atom of Ebselen strongly interacts with some groups typically present in proteins via the chalcogen bond, a weak bonding that has been studied for years in our laboratories; this binding may contribute to the inhibition of the virus replication. This represents an important step forward in the fight against COVID-19,” said one of the researchers, Professor Giuseppe Resnati at the Politecnico di Milano.

  The scientists then elucidated the details of the Ebselen and enzyme binding mechanism. They found that the selenium plays a fundamental role in establishing the interactions that favour the binding of Ebselen to SARS-CoV-2 and to other pathogenic retroviruses in humans such as those of HIV and Hepatitis C.

LEAVE A REPLY

Please enter your comment!
Please enter your name here